Flow Cytometry Diagnostic Antibodies
What are Flow Cytometry Diagnostic Antibodies?
Flow cytometry is a fluorescence-based detection technology that simultaneously measures multiple characteristics of individual cells suspended in a fluid stream, such as cell population counting, protein abundance, or cell cycle status. Flow cytometry diagnostic antibodies refer to fluorescently labeled antibodies specifically designed for flow cytometry applications. These antibodies bind with high specificity to target proteins (antigens) on the cell surface or intracellularly, generating fluorescent signals that enable the analysis of cellular properties, functions, or states. This facilitates disease diagnosis, cell classification, and biomarker detection. In clinical diagnostics, these antibodies are routinely used for analyzing patient samples such as blood, tissues, or body fluids to identify abnormal cell populations, supporting precise diagnosis of tumors, immunodeficiencies, or infectious diseases.
GeneMedi has launched the SOLIDEX™ - CDEx Flow Cytometry Antibodies (PE/APC/FITC/Biotin) series, a product line specifically engineered for flow cytometry (FC). These fluorescently conjugated, highly specific monoclonal antibodies enable multi-parameter detection of cell surface markers. The SOLIDEX™ - CDEx Flow Cytometry Antibodies are widely applied in immunology research, tumor diagnostics, and infectious disease monitoring. The series covers a broad range of cellular markers, with each antibody available in four conjugation formats (PE, APC, FITC, Biotin) to support multicolor panel design and flexible experimental configurations.
Applications of Flow Cytometry Diagnostic Antibodies
The SOLIDEX™ - CDEx Flow Cytometry Antibodies (PE/APC/FITC/Biotin) focus on immunophenotyping of immune cell subsets and provide the following antibody products targeting key markers: CD66b, CD34, NCAM1 (CD56), CD14, CD19, CD3E, CD4, CD8, TCR, CD138, CD45RA, CD45, CD16, CD25. These antibodies are suitable for a wide range of clinical and research scenarios, ensuring accurate cell phenotyping and informed diagnostic decisions.
|
Biomarker |
Clinical Applications |
Research Applications |
|
CD66b |
Identifying neutrophil-like monocytes in the tumor microenvironment for cancer immunotherapy monitoring and prognostic assessment |
Neutrophil subpopulation classification in flow cytometry; granulocyte degranulation studies (e.g., changes in CD66b and CD11b expression). |
|
CD34 |
Hematopoietic stem cell transplantation monitoring is used for the diagnosis of bone marrow diseases such as leukemia typing. |
Progenitor cell identification and immune cell differentiation research |
|
NCAM1 (CD56) |
Applications of NK cell monitoring in cancer and infection for disease severity assessment. |
NK cell subset characterization (CD56 low/high); T cell subset analysis, such as NKT cells; innate immune cytotoxicity studies. |
|
CD14 |
Monitoring of monocytes/macrophages in tumors (such as lung cancer) and inflammatory diseases (such as osteoarthritis) is used to assess disease severity and prognosis. |
MDSC identification in immunosuppression studies; macrophage polarization (M1/M2) analysis. |
|
CD19 |
Diagnosis of B-cell-related diseases such as lymphoma and leukemia; monitoring of B-cell depletion during CAR-T therapy. |
B cell maturation and subset characterization (immature/memory/plasma blasts) |
|
CD3E |
Application of T-cell counting in monitoring immunodeficiency (such as HIV) and transplantation. |
Overall characterization and activation status analysis of T cells. |
|
CD4 |
HIV progression monitoring; assessment of autoimmune diseases and transplant rejection. |
Research on Th cell subset polarization (e.g., Th1/Th2/Th17). |
|
CD8 |
Monitoring of cytotoxic T cells in viral infections and cancer. |
Research on effector and memory T cells. |
|
TCR |
Assessment of T-cell receptor diversity in cancer immunotherapy (e.g., TCR-T) and infections; diagnosis of cutaneous T-cell lymphoma. |
Identification of γδ T cells; TCR sequencing and affinity studies. |
|
CD138 |
Diagnosis of multiple myeloma (plasma cell marker); monitoring of plasma cell disorders. |
Research on terminal B-cell differentiation. |
|
CD45RA |
Monitoring of naive T cells in transplantation and immune reconstitution. |
Distinction between naive and memory T cells. |
|
CD45 |
Leukocyte subtyping in the diagnosis of hematological malignancies. |
Overall characterization of hematopoietic cells; used for immune cell gating. |
|
CD16 |
Monitoring of NK cells and monocytes in infections (e.g., COVID-19) and cancer. |
Analysis of cytotoxic subsets and maturation status. |
|
CD25 |
Monitoring of regulatory T cells in transplantation, autoimmune diseases, and cancer immunotherapy. |
Identification and functional studies of Treg cells. |
Product list of Flow Cytometry Diagnostic Antibodies
Product Features
High Specificity and Affinity:
Monoclonal antibody design ensures targeted binding and minimizes cross-reactivity.
Multicolor Compatibility:
Available in four conjugations—PE, APC, FITC, Biotin—fully supporting multicolor panel experiments and compatible with the spectral configurations of mainstream flow cytometers.
Low Background Noise:
Optimized Fc blocking reduces non-specific binding, making these antibodies particularly suitable for the detection of low-expression antigens.
| Cat No | Product Name | Speices | Conjugate | Size | Cell population | Products Information |
|---|---|---|---|---|---|---|
| GM-Tg-hg-MP0250-Ab-3-PE/FITC/APC/Biotin | Anti-Human CD66b monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD66b+ Cell | Details |
| GM-Tg-hg-T66426-Ab-3/4/7/8-PE/FITC/APC/Biotin | Anti-Human CD34 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD34+ Cell | Details |
| GM-Tg-hg-T86323-Ab-1-PE/FITC/APC/Biotin | Anti-Human NCAM1 (CD56) monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | NK cell | Details |
| GM-Tg-hg-T23212-Ab-1-PE/FITC/APC/Biotin | Anti-Human CD14 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD14+ Cell | Details |
| GM-Tg-hg-T56365-Ab-1-PE/FITC/APC/Biotin | Anti-Human CD19 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | B Cell | Details |
| GM-Tg-hg-T87075-Ab-1-PE/FITC/APC/Biotin | Anti-Human CD3E monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | Pan-T cell | Details |
| GM-Tg-hg-T10191-Ab-1/2-PE/FITC/APC/Biotin | Anti-Human CD4 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD4-T Cell | Details |
| GM-Tg-hg-TA040-Ab-1-PE/FITC/APC/Biotin | Anti-Human CD8 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD8-T Cell | Details |
| GM-Tg-hg-MP2610-Ab-3-PE/FITC/APC/Biotin | Anti-Human TCR alpha-beta (abT) monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | TCR+ Cell | Details |
| GM-Tg-hg-T13017-Ab-1-PE/FITC/APC/Biotin | Anti-Human CD138 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | mouse | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD138+ Cell | Details |
| GM-Tg-hg-T43115-8-Ab-4-PE/FITC/APC/Biotin | Anti-Human CD45RA monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD45RA+ Cell | Details |
| GM-Tg-hg-T43115-Ab-4-PE/FITC/APC/Biotin | Anti-Human CD45 monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD45+ Cell | Details |
| GM-Tg-hg-T59001-Ab-3-PE/FITC/APC/Biotin | Anti-human CD16 human monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD16+ Cell | Details |
| GM-Tg-hg-T03313-Ab-1-PE/FITC/APC/Biotin | Anti-human CD25 human monoclonal antibody(mAb)(PE/FITC/APC/Biotin) | humanized | PE/FITC/APC/Biotin | 25T, 100T, 500T | CD25+ cells | Details |
Validation Data
GeneMedi's Flow Cytometry antibodies are validated to detect PBMC-derived specific cell types by flow cytometry.
GeneMedi's antibodies—Anti-Human CD3E, Anti-Human CD4, Anti-Human CD8, Anti-Human CD14, Anti-Human CD19, and Anti-Human NCAM1 (CD56)—are extensively validated for the detection of specific cell types derived from Peripheral Blood Mononuclear Cells (PBMCs) by flow cytometry. These antibodies enable accurate identification and profiling of immune cell subsets within PBMC populations, supporting diverse immunological studies and applications. These antibodies perform reliably in identifying critical immune cell subsets, including T cells, B cells, monocytes, and natural killer (NK) cells, providing essential tools for immunological and therapeutic research.
Comparative studies indicate that GeneMedi's antibody products offer performance on par with Company B's commercial antibodies. This similarity in performance means that researchers can expect comparable levels of sensitivity, specificity, and consistency when using GeneMedi's antibodies. Such equivalency provides researchers with confidence in using GeneMedi's products as effective alternatives, whether for immune profiling, cell population analysis, or functional assays.
Figure 1. GeneMedi's Anti-Human CD3E antibody, Anti-Human CD4 antibody, Anti-Human CD8 antibody, Anti-Human CD14 antibody, Anti-Human CD19 antibody, Anti-Human CD56 antibody, Anti-Human CD45 monoclonal antibody, Anti-Human CD66b monoclonal antibody and Anti-Human CD34 monoclonal antibody are validated to detect PBMC-derived specific cell types byflow cytometry.
A-F. Anti-Human CD3E antibody (A), Anti-Human CD4 antibody (B), Anti-Human CD8 antibody (C), Anti-Human CD14 antibody (D), Anti-Human CD19 antibody (E), Anti-Human NCAM1 (CD56) antibody (F).
G. The Cat number and product name correspond to the antibodies used in this study.
